Jian Ding
Vice President - Translational Research CREATE Medicines
Seminars
Tuesday 21st July 2026
In Vivo Immune Cell Programming with mRNA-LNP Therapeutics
8:30 am
- In vivo CAR mRNA-LNP platform selectively generates CAR-T, CAR-NK, and myeloid CAR cells directly in patients
- Clinically validated with data from 50+ patients and demonstrated tolerable repeat dosing
- Best-in-class in vivo CARs across oncology and autoimmunity, including first clinical responses with in vivo CARs outside blood cancers
